Clinical Trials Logo

Stage IIIC Gastric Cancer clinical trials

View clinical trials related to Stage IIIC Gastric Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04781413 Recruiting - Clinical trials for Stage IIIC Gastric Cancer

Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer

Start date: March 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

In this study, we combine Nab-PTX, S-1 and sintilimab as adjuvant regimen to patients with stage IIIC GC. We are aiming to investigate the recommended dose of this regimen in a phase I study and estimate the toxicity and efficacy of this regimen in a phase II study.

NCT ID: NCT02366819 Recruiting - Clinical trials for Gastric Adenocarcinoma

Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Start date: December 11, 2014
Phase: Phase 4
Study type: Interventional

This pilot clinical trial studies genetic analysis-guided irontecan hydrochloride dosing of modified fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin (mFOLFIRINOX) in treating patients with gastroesophageal or stomach cancer that has spread from where it started to nearby tissue or lymph nodes. Drugs used in chemotherapy, such as fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Leucovorin calcium may also help fluorouracil work better. Genetic analysis may help doctors determine what dose of irinotecan hydrochloride patients can tolerate.